Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

NCT04271202 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

64

Enrollment

OTHER

Sponsor class

Conditions

Chronic Migraine

Interventions

DRUG: Emgality 120 MG in 1 ML Prefilled Syringe

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

[object Object]